Given this central role of STAT5 activation in mediating the oncogenic effects of FLT3-ITD, it is expected that molecules inhibiting STAT5 may inhibit the survival and the proliferation of FLT3-ITD+ AML cells. Here, FLT3 is linked to acute myeloid leukemia.